Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate

Eitemau Tebyg

• Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
  gan: Jesper Jørgensen, et al.
  Cyhoeddwyd: (2019-01-01)
• Reimbursement of licensed cell and gene therapies across the major European healthcare markets
  gan: Jørgensen, Jesper, et al.
  Cyhoeddwyd: (2015)
• Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
  gan: Jørgensen, Jesper, et al.
  Cyhoeddwyd: (2020)
• Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
  gan: Jørgensen, Jesper, et al.
  Cyhoeddwyd: (2017)
• The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
  gan: Jesper Jørgensen, et al.
  Cyhoeddwyd: (2018-01-01)